SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACO AMONG HIV-1 MEN AND WOMEN

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是对78名HIV感染者（39名男性和39名女性）的药代动力学（PK）评价，他们目前正在服用洛匹那韦/利托那韦（LPV/RTV）作为抗逆转录病毒治疗方案的一部分。 将在LPV/RTV早晨给药前和给药后12小时内采集血浆样本。 这是第一项关于HIV感染者中LPV/RTV PK性别差异的大型前瞻性研究。 所获得的数据将用作提出更大规模研究的基础，这些研究使用额外的药物，专门研究性别之间疗效和毒性的潜在差异，并刺激对这种差异的机制基础的研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a pharmacokinetic (PK) evaluation of 78 HIV-infected individuals (39 men and 39 women) who are currently taking lopinavir/ritonavir (LPV/RTV) as part of their antiretroviral regimen. Plasma samples will be obtained prior to and up to 12 hours after the administration of the morning dose of LPV/RTV. This is the first large prospective study of sex differences in the PK of LPV/RTV in HIV-infected individuals. This data obtained will be used as a basis for proposing larger studies with additional drugs specifically looking at potential differences in efficacy and toxicity between the sexes, and to stimulate study into the mechanistic basis of this difference.